{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-043233","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.392182+00:00","generated_at":"2026-06-04T02:10:13.089268+00:00","sec_items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Onconova merges with Trawsfynydd, changes name to Traws Pharma, raises $14M PIPE","bullets":["Acquired Trawsfynydd in reverse merger; issued 3,549,538 common shares and 10,359 Series C preferred shares to Trawsfynydd stockholders.","Company renamed Traws Pharma, Inc.; ticker changed to TRAW on Nasdaq.","New leadership: Werner Cautreels appointed CEO; Iain Dukes Executive Chairman; Nikolay Savchuk COO; Robert Redfield CMO; C. David Pauza CSO Virology.","Concurrent $14M PIPE financing: sold 496,935 common shares and 1,578 Series C preferred shares to Torrey Pines affiliate and OrbiMed.","CVRs issued to all common shareholders as of April 15, 2024, entitling to 43.7% of net proceeds from sale of rigosertib/narazaciclib or 6.24% of net sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-043233","json":"https://secwatch.observer/filing/0001104659-24-043233.json","markdown":"https://secwatch.observer/filing/0001104659-24-043233.md","text":"https://secwatch.observer/filing/0001104659-24-043233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/tm2410784d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:10:13.089268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0814ff8fbe","claim":"C. David Pauza was appointed as Chief Scientific Officer, Virology at Traws Pharma, Inc..","evidence_excerpt":"In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer, Virology"}],"fact_type":"executive_change"},{"claim_id":"08c2ea02c5","claim":"Nikolay Savchuk was appointed as Chief Operating Officer at Traws Pharma, Inc..","evidence_excerpt":"appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"0ba349a911","claim":"Iain Dukes was appointed as Executive Chairman at Traws Pharma, Inc..","evidence_excerpt":"appointed Iain Dukes as a director and Executive Chairman of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"1e78a004b5","claim":"Peter Atadja resigned as Director at Traws Pharma, Inc..","evidence_excerpt":"accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3d800ee9ed","claim":"Viren Mehta resigned as Director at Traws Pharma, Inc..","evidence_excerpt":"accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5281fb6271","claim":"Werner Cautreels was appointed as Chief Executive Officer at Traws Pharma, Inc..","evidence_excerpt":"appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d2fd6b55de","claim":"Mark Guerin departed as Chief Financial Officer at Traws Pharma, Inc..","evidence_excerpt":"Mark Guerin remained as the Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned as COO and remained as CFO"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d60a533938","claim":"Steven M. Fruchtman resigned as Director at Traws Pharma, Inc..","evidence_excerpt":"accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e6ea876ca5","claim":"Robert Redfield was appointed as Chief Medical Officer at Traws Pharma, Inc..","evidence_excerpt":"In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"f8a6529a76","claim":"Jerome Groopman resigned as Director at Traws Pharma, Inc..","evidence_excerpt":"accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f91bec237d","claim":"Steven M. Fruchtman was appointed as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..","evidence_excerpt":"Dr. Steven M. Fruchtman remained as the President of the Company and was appointed Chief Scientific Officer, Oncology","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"remained as the President of the Company and was appointed Chief Scientific Officer, Oncology"},{"label":"Role","value":"President and Chief Scientific Officer, Oncology"}],"fact_type":"executive_change"},{"claim_id":"4c6b3dcc273138e9de89e9fc5c490b07dbaec41c","claim":"Traws Pharma, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock on April 1, 2024 (effective 2024-04-01).","evidence_excerpt":"On April 1, 2024, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Merger referenced in Item 1.01 above.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-01"}],"fact_type":"governance_change"},{"claim_id":"8b18d5dfa16a76c4d710f3e53632c742d020fd9c","claim":"Traws Pharma, Inc.: Changed company name to Traws Pharma, Inc. via certificate of amendment to Tenth Amended and Restated Certificate of Incorporation on April 2, 2024 (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024, the Company changed its name to Traws Pharma, Inc. pursuant to a certificate of amendment to its Tenth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-02"}],"fact_type":"governance_change"},{"claim_id":"79849c226c15012d797da95e73832975ae26db27","claim":"Traws Pharma, Inc. completed an acquisition involving Trawsfynydd Therapeutics, Inc. for 3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock (closed 2024-04-01).","evidence_excerpt":"shares of capital stock of Trawsfynydd immediately prior to the effective time of the First Merger, the Company issued to the stockholders of Trawsfynydd an aggregate of (A) 3,549,538 shares of common stock of the Company, par value $0.01 per share (the “Common Stock”) and (B) 10,359.0916 shares of Series C Preferred Stock (as defined and described below). Each","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm","confidence":0.99,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Trawsfynydd Therapeutics, Inc."},{"label":"Consideration","value":"3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock"},{"label":"Closing","value":"2024-04-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}